This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings-surprise: Archive
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
URGNNegative Net Change CRBUNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
TEGNA Inc. (TGNA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
TEGNA (TGNA) delivered earnings and revenue surprises of +12.36% and +1.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
TGNANegative Net Change BILINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
WhiteHorse Finance (WHF) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
WhiteHorse (WHF) delivered earnings and revenue surprises of +7.41% and +4.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
WHFPositive Net Change HRZNPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
QURENegative Net Change DARENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Aaon (AAON) Misses Q4 Earnings Estimates
by Zacks Equity Research
Aaon (AAON) delivered earnings and revenue surprises of -12.85% and +14.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
AAONPositive Net Change TGENNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of +1,053.85% and +276.79%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
CGENPositive Net Change ARCTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +252.25% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ASTHPositive Net Change TELANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ADT (ADT) Q4 Earnings Surpass Estimates
by Zacks Equity Research
ADT (ADT) delivered earnings and revenue surprises of +15.00% and -0.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ADTNegative Net Change IDNPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of +84.62% and +5.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
XERSNegative Net Change PROFNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sealed Air (SEE) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Sealed Air (SEE) delivered earnings and revenue surprises of +7.15% and +4.57%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
SEEPositive Net Change KRTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank